KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Organon (OGN) Cash & Equivalents (2020 - 2025)

Historic Cash & Equivalents for Organon (OGN) over the last 6 years, with Q3 2025 value amounting to $672.0 million.

  • Organon's Cash & Equivalents fell 1192.66% to $672.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $672.0 million, marking a year-over-year decrease of 1192.66%. This contributed to the annual value of $675.0 million for FY2024, which is 259.74% down from last year.
  • According to the latest figures from Q3 2025, Organon's Cash & Equivalents is $672.0 million, which was down 1192.66% from $599.0 million recorded in Q2 2025.
  • Organon's Cash & Equivalents' 5-year high stood at $1.0 billion during Q3 2021, with a 5-year trough of $141.0 million in Q1 2021.
  • In the last 5 years, Organon's Cash & Equivalents had a median value of $672.0 million in 2025 and averaged $604.6 million.
  • Its Cash & Equivalents has fluctuated over the past 5 years, first skyrocketed by 604166.67% in 2021, then plummeted by 5049.6% in 2022.
  • Quarter analysis of 5 years shows Organon's Cash & Equivalents stood at $737.0 million in 2021, then decreased by 4.21% to $706.0 million in 2022, then decreased by 1.84% to $693.0 million in 2023, then decreased by 2.6% to $675.0 million in 2024, then fell by 0.44% to $672.0 million in 2025.
  • Its Cash & Equivalents was $672.0 million in Q3 2025, compared to $599.0 million in Q2 2025 and $547.0 million in Q1 2025.